Maricann Group (CNSX:MARI) Price Target Raised to $13.00 at BMO Capital Markets

Maricann Group (CNSX:MARI) had its price target boosted by BMO Capital Markets from $12.00 to $13.00 in a research report released on Wednesday morning,BayStreet.CA reports.

Other equities analysts have also issued reports about the company. National Bankshares boosted their target price on Maricann Group from $7.50 to $11.00 and gave the stock an “outperform” rating in a research report on Friday, July 4th. Raymond James Financial boosted their target price on Maricann Group from $6.50 to $11.50 in a research report on Thursday, August 21st. Finally, Beacon Securities boosted their target price on Maricann Group from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $12.63.

Maricann Group Stock Performance

Maricann Group has a 12-month low of $0.87 and a 12-month high of $3.60.

About Maricann Group

Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.